Literature DB >> 16728585

IGF-I, IGFBP-3 and breast cancer risk in women: The European Prospective Investigation into Cancer and Nutrition (EPIC).

S Rinaldi1, P H M Peeters, F Berrino, L Dossus, C Biessy, A Olsen, A Tjonneland, K Overvad, F Clavel-Chapelon, M C Boutron-Ruault, B Téhard, G Nagel, J Linseisen, H Boeing, P H Lahmann, A Trichopoulou, D Trichopoulos, M Koliva, D Palli, S Panico, R Tumino, C Sacerdote, C H van Gils, P van Noord, D E Grobbee, H B Bueno-de-Mesquita, C A Gonzalez, A Agudo, M D Chirlaque, A Barricarte, N Larrañaga, J R Quiros, S Bingham, K T Khaw, T Key, N E Allen, A Lukanova, N Slimani, R Saracci, E Riboli, R Kaaks.   

Abstract

Blood concentrations of insulin-like growth factor-I (IGF-I) and insulin-like growth factor binding protein-3 (IGFBP-3) have recently been associated with breast cancer risk, notably in women who developed breast cancer at a young age. Prospective studies published so far, however, were relatively small and odds ratio (OR) estimates imprecise. We present the results of a large prospective case-control study nested within the European Prospective Investigation into Cancer and Nutrition on total IGF-I, IGFBP-3 and breast cancer risk including 1081 incident cases of invasive breast cancer and 2098 matched control subjects. Increasing IGF-I and IGFBP-3 concentrations were associated with a significant increase in breast cancer risk in women who developed breast cancer after 50 years of age (highest vs lowest quintile OR 1.38 (95% confidence interval (CI) 1.02-1.86), P = 0.01, and 1.44 (95% CI 1.04-1.98), P = 0.01, respectively), but no relationship was observed in younger women (OR = 1.03 (95% CI 0.60-1.77), P = 0.81 for IGF-I, and OR = 0.92 (95% CI 0.50-1.70), P = 0.69 for IGFBP-3). There was, however, significant heterogeneity in the relationship of breast cancer with serum IGF-I and IGFBP-3 levels depending on the time interval between blood donation and tumor diagnosis. A reduction in breast cancer risk with increasing IGF-I concentrations was observed in cases with a diagnosis of cancer less than 2 years after blood donation, (OR = 0.76 (95% CI 0.57-1.03)), while an increase in risk was observed for women with a later diagnosis (above or equal to two years after blood collection, OR = 1.51 (95% CI 1.19-1.91)). A similar pattern was observed for IGFBP-3. This study confirms previous findings for an association of serum IGF-I and IGFBP-3 concentrations with breast cancer risk, particularly for women with a later diagnosis of cancer, but it does not support the hypothesis of an involvement of IGF-I in younger women.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16728585     DOI: 10.1677/erc.1.01150

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  50 in total

1.  Expression of IGF1R in normal breast tissue and subsequent risk of breast cancer.

Authors:  Rulla M Tamimi; Graham A Colditz; Yihong Wang; Laura C Collins; Rong Hu; Bernard Rosner; Hanna Y Irie; James L Connolly; Stuart J Schnitt
Journal:  Breast Cancer Res Treat       Date:  2011-01-01       Impact factor: 4.872

Review 2.  Insidious changes in stromal matrix fuel cancer progression.

Authors:  Fayth L Miles; Robert A Sikes
Journal:  Mol Cancer Res       Date:  2014-01-22       Impact factor: 5.852

3.  Dietary calcium, vitamin D, and breast cancer risk in women: findings from the SUN cohort.

Authors:  Cesar I Fernandez-Lazaro; Andrea Romanos-Nanclares; Rodrigo Sánchez-Bayona; Alfredo Gea; Carmen Sayon-Orea; Miguel A Martinez-Gonzalez; Estefanía Toledo
Journal:  Eur J Nutr       Date:  2021-04-05       Impact factor: 5.614

4.  Developmental stage determines estrogen receptor alpha expression and non-genomic mechanisms that control IGF-1 signaling and mammary proliferation in mice.

Authors:  Jie Tian; Thomas R Berton; Stephanie H Shirley; Isabel Lambertz; Irma B Gimenez-Conti; John DiGiovanni; Kenneth S Korach; Claudio J Conti; Robin Fuchs-Young
Journal:  J Clin Invest       Date:  2011-12-19       Impact factor: 14.808

5.  Metabolic effects of pioglitazone in chemically-induced mammary carcinogenesis in rats.

Authors:  Bianka Bojková; Miroslava Garajová; Martin Péč; Peter Kubatka; Karol Kajo; Marián Mokáň; Monika Kassayová; Peter Orendáš; Terézia Kisková; Eva Ahlersová; Ivan Ahlers
Journal:  Pathol Oncol Res       Date:  2011-06-07       Impact factor: 3.201

Review 6.  Growth hormone and insulin-like growth factor-I in the transition from normal mammary development to preneoplastic mammary lesions.

Authors:  David L Kleinberg; Teresa L Wood; Priscilla A Furth; Adrian V Lee
Journal:  Endocr Rev       Date:  2008-12-15       Impact factor: 19.871

7.  Plasma IGF-1 and IGFBP-3 may be imprecise surrogates for breast concentrations: an analysis of healthy women.

Authors:  Adana A Llanos; Theodore M Brasky; Ramona G Dumitrescu; Catalin Marian; Kepher H Makambi; Bhaskar V S Kallakury; Scott L Spear; David J Perry; Rafael J Convit; Mary E Platek; Lucile L Adams-Campbell; Jo L Freudenheim; Peter G Shields
Journal:  Breast Cancer Res Treat       Date:  2013-03-02       Impact factor: 4.872

8.  Disease evidence for IGFBP-2 as a key player in prostate cancer progression and development of osteosclerotic lesions.

Authors:  David J Degraff; Adam A Aguiar; Robert A Sikes
Journal:  Am J Transl Res       Date:  2009-01-20       Impact factor: 4.060

9.  Associations of insulin-like growth factor and insulin-like growth factor binding protein-3 with mortality in women with breast cancer.

Authors:  Catherine Duggan; Ching-Yun Wang; Marian L Neuhouser; Liren Xiao; Ashley Wilder Smith; Kerryn W Reding; Richard N Baumgartner; Kathy B Baumgartner; Leslie Bernstein; Rachel Ballard-Barbash; Anne McTiernan
Journal:  Int J Cancer       Date:  2012-09-01       Impact factor: 7.396

10.  Clinical and Translational Results of a Phase II, Randomized Trial of an Anti-IGF-1R (Cixutumumab) in Women with Breast Cancer That Progressed on Endocrine Therapy.

Authors:  William J Gradishar; Denise A Yardley; Rachel Layman; Joseph A Sparano; Ellen Chuang; Donald W Northfelt; Gary N Schwartz; Hagop Youssoufian; Shande Tang; Ruslan Novosiadly; Amelie Forest; Tuan S Nguyen; Jan Cosaert; Dmitri Grebennik; Paul Haluska
Journal:  Clin Cancer Res       Date:  2015-08-31       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.